AMAG Pharmaceuticals has submitted a supplemental new drug application (sNDA) for intravenous (IV) use of Feraheme injection, to FDA. The company is seeking approval for the label expansion of Feraheme to include all iron deficiency ...
Tags: Feraheme Injection, AMAG, SNDA